Biotech Startups

Sydnexis is a privately held biopharmaceutical company developing SYD-101, a proprietary low-dose atropine formulation in Phase 3 clinical trials to slow the progression of pediatric progressive myopia. The company focuses on pediatric ophthalmology and children's eye care.

3 investors

Syenex provides cell delivery technologies and contract development services for therapeutic cell engineering, serving biopharmaceutical companies developing cell-based therapies. The company integrates cell engineering and delivery capabilities with regulatory support for clinical development.

3 investors

Synaffix develops antibody-drug conjugate (ADC) technology, providing linker-payload platforms that attach small-molecule, peptide, and protein-based payloads to antibodies for use in targeted cancer therapies. The company has been integrated into Lonza's Advanced Synthesis business platform.

3 investors

Syndeio Biosciences is a synapse-focused biotech developing precision neurotherapeutics for neuropsychiatric, mental health, and cognitive disorders such as depression and Alzheimer's. Its proprietary Boost Platform models synapse pharmacology, and its pipeline includes NMDA receptor positive allosteric modulators (zelquistinel and apimostinel) in Phase 2 clinical trials.

3 investors

Synfini provides AI-driven drug discovery collaboration services that help researchers advance targets and hits into optimized, patentable chemistry. The company offers a platform combining virtual screening, scaffold hopping, synthesis planning, and parallel library synthesis to accelerate early-stage drug discovery.

3 investors

A drug discovery company founded by an experienced medicinal chemistry team with expertise in successful pharmaceutical development and clinical advancement.

3 investors

SynOx Therapeutics develops emactuzumab, a monoclonal antibody treatment for tenosynovial giant cell tumours (TGCT) and macrophage-mediated diseases. The company focuses on bringing a differentiated drug candidate through clinical development and commercialisation to address unmet patient needs in rare and debilitating diseases.

3 investors

Syntetica develops chemical recycling technologies to make polymers circular, starting with nylon, turning waste into new materials. The company works on green chemistry and process scale-up for industrial applications.

3 investors

Synvect develops ngSIT (next-generation sterile insect technique) technology to control mosquito-borne disease vectors through genetic engineering. The company serves public health organizations and disease control programs targeting mosquito-borne diseases worldwide.

3 investors

Syros Pharmaceuticals is a Massachusetts gene-control biotech developing small molecules that regulate disease gene expression.

3 investors

Tahoe generates large-scale perturbative single-cell biological data and builds ML models and autonomous research agents that predict cellular responses and validate hypotheses for drug discovery and biological research. It combines lab-generated data with AI models to provide biological ground truth for reasoning models.

3 investors

Tallac Therapeutics is a clinical-stage biopharmaceutical company developing oligonucleotide-based antibody conjugates (TRAAC candidates) designed to deliver immune-activating agents to tumor microenvironments for oncology indications. The company has two programs currently in clinical trials.

3 investors

TandemAI combines AI-driven techniques with physics-based computational methods, backed by in-house high-performance computing and wet lab operations, to support drug discovery. It offers a cloud-enabled platform for research partners and the scientific community in the pharmaceutical and biotech space.

3 investors

Taudia develops ultrasensitive biomarker detection technology for neurodegenerative disease quantitation, serving researchers, biopharma teams, and clinicians through blood-based diagnostic tools.

3 investors

Telum Therapeutics develops antimicrobial drugs using synthetic biology and AI-driven machine learning, specializing in engineered lytic proteins to address multidrug-resistant infections. The company serves pharmaceutical and healthcare markets focused on treating infectious diseases with high unmet medical needs.

3 investors

TenSixty uses machine learning and cell biology expertise to identify novel antibody targets on cancer cells for the development of new cancer therapeutics. The company combines AI with high-throughput technologies to discover improved drug candidates for oncology.

3 investors

Terremoto Biosciences is a clinical-stage biotech developing precision therapies for oncology and genetic diseases using lysine-targeted covalent chemistry. It pursues both best-in-class treatments against known drug targets and first-in-class medicines against previously undruggable targets.

3 investors

TeselaGen offers a cloud-based platform for managing the complete design-build-test-learn cycle in biological research and synthetic biology workflows. The platform connects sequence design, laboratory execution, data capture, and machine-learning analysis to eliminate data silos and ensure traceability across experimental processes.

3 investors

Tetsuwan operates a cloud lab and automation platform called ResearchOS that lets researchers configure, simulate, and run biology experiments from their browser without physical lab access. Users describe procedures and variables in natural language or by uploading files, and the system compiles them into executable robotic automation scripts.

3 investors

Tevard Biosciences develops tRNA-based therapies to provide durable cures for rare genetic diseases caused by nonsense mutations, including cardiomyopathy, muscular dystrophy, and epilepsy. The company uses suppressor tRNA technology to restore full-length protein production across affected organs and tissues.

3 investors

The Akkermansia Company produces a consumer dietary supplement containing proprietary Akkermansia MucT™ bacteria formulated to support weight management, glucose metabolism, gut health, and immune function.

3 investors

The company uses molecular simulation and AI to engineer breakthrough medicines.

3 investors

The Foundry is a medical device incubator that identifies unmet clinical needs and builds companies around new technologies to address them, working with physician collaborators to develop products from concept to market. It operates a facility with office space, R&D and wet labs, chemistry development, a machine shop, and a clean room.

3 investors

Theradaptive develops protein engineering technology that modifies recombinant proteins into material-binding variants for targeted therapeutic delivery, aiming to improve efficacy and reduce off-target effects. Its applications span more than a dozen clinical indications including spinal fusion, orthopedics, soft tissue repair, and targeted chemotherapeutics.

3 investors